According to our data, convalescent patients with mild and moderate COVID-19 formed a broad spectrum of SARS-CoV-2-specific CD4+ T cell subsets, but they predominantly expressed CCR6 and were capable of inducing type 3 immunity on mucosal tissues. The gene discussed is CD4; the disease is COVID-19.